UK Shuffle Will Undermine Stem Cell Progress
This article was originally published in RAJ Devices
Executive Summary
Karen Finn argues that while proposals by the Department of Health aim to reduce the number of health arm's-length bodies and deliver significant cost savings, they might have serious consequences for stem cell advances on the global front.
You may also be interested in...
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
US FDA scrutiny of DTC genetic tests continues
The US FDA's devices unit has written to three genetic testing companies warning them that they may be marketing their products and services without clearance by the agency.